Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$118.05+2.10%
Close 2026-07-07 · 1-day change
Reading INCY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track INCY free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading INCY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track INCY free→QuarterlyIQ Insights · INCY
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 5,361.0 | 5,141.2 | 4,241.2 | 3,695.6 | 2,666.7 | 2,666.7 | 2,666.7 | 2,158.8 | 1,105.7 | 1,105.7 | 1,105.7 | 753.8 | 297.1 | 297.1 | 297.1 | 94.5 |
| Total Revenues | — | — | — | — | 2,666.7 | 2,666.7 | 2,666.7 | 2,158.8 | 1,105.7 | 1,105.7 | 1,105.7 | 753.8 | 297.1 | 297.1 | 297.1 | 94.5 |
| Cost of Revenues | 403.5 | 372.1 | 312.1 | 255.0 | 131.3 | 131.3 | 131.3 | 114.2 | 58.2 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 1,378.6 | 1,376.2 | 1,242.2 | 1,161.3 | 516.9 | 516.9 | 516.9 | 468.7 | 303.3 | 303.3 | 303.3 | 196.6 | 85.4 | 85.4 | 85.4 | 58.2 |
| R&D Expenses | 2,128.8 | 2,050.2 | 2,606.8 | 1,627.6 | 2,215.9 | 2,215.9 | 2,215.9 | 1,154.1 | 581.9 | 581.9 | 581.9 | 479.5 | 210.4 | 210.4 | 210.4 | 178.7 |
| Operating Income | 1,610.8 | 1,514.9 | 61.4 | 620.5 | (263.7) | (263.7) | (263.7) | 402.0 | 145.0 | 145.0 | 145.0 | 50.7 | 1.1 | 1.1 | 1.1 | (143.2) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | 2.6 | 2.2 | 2.2 | 2.2 | 1.9 | 38.7 | 38.7 | 38.7 | 45.6 | 46.1 | 46.1 | 46.1 | 43.8 |
| Interest & Investment Income | 116.4 | 105.6 | 128.7 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Writedown | — | 76.3 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 1,773.9 | 1,664.5 | 316.6 | 834.2 | (232.2) | (232.2) | (232.2) | 486.8 | 107.4 | 107.4 | 107.4 | 7.6 | (44.1) | (44.1) | (44.1) | — |
| Income Tax Expense | 342.1 | 377.8 | 284.0 | 236.6 | 63.5 | 63.5 | 63.5 | 39.9 | 3.2 | 3.2 | 3.2 | 1.0 | 0.2 | 0.2 | 0.2 | — |
| Net Income | ||||||||||||||||
| Net Income | 1,431.8 | 1,286.7 | 32.6 | 597.6 | (295.7) | (295.7) | (295.7) | 446.9 | 104.2 | — | — | — | — | — | — | — |
| Per Share | ||||||||||||||||
| Basic EPS | 7.18 | 6.59 | 0.16 | 2.67 | (1.36) | (1.36) | (1.36) | 2.08 | 0.55 | 0.55 | 0.55 | 0.04 | (0.22) | 0.14 | 0.14 | 0.26 |
| Diluted EPS | 6.92 | 6.41 | 0.15 | 2.65 | (1.36) | (1.36) | (1.36) | 2.05 | 0.54 | 0.54 | 0.54 | 0.03 | (0.22) | 0.14 | 0.14 | 0.24 |
| Revenue per Share | 25.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 199.3 | 195.2 | 207.1 | 223.6 | 218.1 | 218.1 | 218.1 | 214.9 | 187.9 | 187.9 | 187.9 | 179.6 | 169.9 | 131.7 | 131.7 | 125.4 |
| Diluted Weighted Avg Shares | 206.8 | 200.7 | 210.5 | 225.9 | 218.1 | 218.1 | 218.1 | 217.7 | 194.1 | 194.1 | 194.1 | 187.3 | 169.9 | 139.1 | 139.1 | 125.4 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 1,608.1 | 150.6 | 703.2 | (211.9) | (211.9) | (211.9) | 456.5 | 203.4 | 203.4 | 203.4 | 95.5 | 31.1 | 31.1 | 31.1 | (116.2) |
| EBIT | 1,610.8 | 1,514.9 | 61.4 | 620.5 | (263.7) | (263.7) | (263.7) | 402.0 | 145.0 | 145.0 | 145.0 | 50.7 | 1.1 | 1.1 | 1.1 | (143.2) |
| Effective Tax Rate | 19.3% | 22.7% | 89.7% | 28.4% | -27.3% | -27.3% | -27.3% | 8.2% | 3.0% | 3.0% | 3.0% | 13.6% | -0.4% | -0.4% | -0.4% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.